Lisata Therapeutics Ownership
| LSTA Stock | USD 2.58 0.15 5.49% |
Shares in Circulation | First Issued 1994-12-31 | Previous Quarter 8.3 M | Current Value 8.3 M | Avarage Shares Outstanding 1.3 M | Quarterly Volatility 3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Lisata |
Lisata Stock Ownership Analysis
About 19.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lisata Therapeutics recorded a loss per share of 2.51. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 15th of September 2022. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease andor promote the regeneration of damaged tissue. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Lisata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people. To find out more about Lisata Therapeutics contact BSc B at 908 842 0100 or learn more at https://www.lisata.com.Besides selling stocks to institutional investors, Lisata Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lisata Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lisata Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lisata Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Lisata Therapeutics Insider Trades History
About 19.0% of Lisata Therapeutics are currently held by insiders. Unlike Lisata Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lisata Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lisata Therapeutics' insider trades
Lisata Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lisata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lisata Therapeutics backward and forwards among themselves. Lisata Therapeutics' institutional investor refers to the entity that pools money to purchase Lisata Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tower Research Capital Llc | 2024-09-30 | 1.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.5 K | Ubs Group Ag | 2024-09-30 | 125 | Royal Bank Of Canada | 2024-09-30 | 52.0 | Jpmorgan Chase & Co | 2024-09-30 | 15.0 | Barclays Plc | 2024-09-30 | 7.0 | Wells Fargo & Co | 2024-09-30 | 1.0 | Advisor Group Holdings, Inc. | 2024-09-30 | 1.0 | Citigroup Inc | 2024-09-30 | 0.0 | Bml Capital Management Llc | 2024-09-30 | 284.7 K | Vanguard Group Inc | 2024-09-30 | 186.4 K |
Lisata Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lisata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lisata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lisata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 3000 shares by James Nisco of Lisata Therapeutics at 3.0 subject to Rule 16b-3 | ||
James Nisco over six months ago Disposition of 4000 shares by James Nisco of Lisata Therapeutics at 3.08 subject to Rule 16b-3 | ||
Buck Kristen K over six months ago Disposition of 50103 shares by Buck Kristen K of Lisata Therapeutics at 1.28 subject to Rule 16b-3 | ||
Wei Eric 1 over a year ago Lisata Therapeutics exotic insider transaction detected |
Lisata Therapeutics Corporate Filings
8K | 3rd of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 21st of August 2024 Other Reports | ViewVerify | |
| 15th of July 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lisata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.51) | Return On Assets (0.29) | Return On Equity (0.44) |
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.